First in-human cases in India

Asia’s First POEM procedure undertaken using Speedboat

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that the first mentored, in-human use of its Speedboat device has taken place in India. This announcement follows on from the framework distribution agreement the Company signed with Meditek Systems in September 2019 to provide clinical in-country training, mentoring and market seeding in India for Creo’s CROMA Advanced Energy Platform and suite of products.

To date, Medical staff from six key healthcare institutions across India have completed training as part of Creo’s Clinical Education Programme and the start of in-country mentoring was marked with the first 2 upper GI POEM (Peroral Endoscopic Myotomy) procedures being performed using Speedboat. These are the first POEM procedures in India carried out using the Speedboat device and show the significant advances made towards the future of endoscopic surgery.

The procedures were performed by Dr Amit Maydeo and Dr Gaurav Patil at the BIDS (Baldota Institute of Digestive Sciences) hospital in Mumbai. Dr Maydeo is currently the Chairman of the BIDS hospital and President of the Association of Interventional GI Endoscopy of India. Both cases were highly successful with Dr Maydeo citing “the microwave coagulation aspect of this device is excellent and not having to interchange devices mid-procedure makes this a great advancement in technology”. With further mentored clinical cases planned in the coming days in Delhi, Pune and Hyderabad, the expansion of Speedboat and the CROMA Advanced Energy Platform continues to gather pace.

As well as India and the US, patients have now been successfully treated using the Speedboat device powered by Creo’s CROMA Advanced Energy platform in the UK, South Africa and Mainland Europe.

About Speedboat

Creo’s Speedboat device is the first in a range of GI devices to be cleared for use with the CROMA Advanced Energy Platform, which uniquely combines bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation.

Craig Gulliford, Chief Executive Officer of Creo, commented:

We are delighted to hear that Creo’s Speedboat device has been rolled out in the BIDS hospital and that the first live procedures have been a success, and are due to be followed by other procedures this week. India is one of the fastest growing healthcare markets in the world and is rapidly evolving in pioneering clinical practice. We look forward to further positive news on the subsequent surgeries.

Posted 11/20/19

For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.

Further news

19 March 2024

Welsh Labour Leader visits Creo’s facilities

Read

05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi

Read

31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific

Read

10 January 2024

First Use of Speedboat® UltraSlim in Latin America

Read

13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch

Read

01 November 2023

Speedboat® UltraSlim: US FDA Clearance

Read

25 October 2023

Speedboat UltraSlim: EU launch accelerated by 18 months

Read

12 September 2023

Half Year Report: H1-2023

Read

19 June 2023

Speedboat Inject cleared for upper GI use in Europe

Read

01 June 2023

Speedboat™ Inject selected by NICE for assessment

Read